Clinical Trials Browser

Phase 2 × INDUSTRY × Lymphoma, T-Cell, Peripheral × Clear all

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Phase 2 Active not recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT06511895 2025-12-24

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Phase 2 Completed

Lymphoma, T-Cell, Peripheral

NCT04703192 2025-12-09

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Phase 2 Active not recruiting

155 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT06511869 2025-07-04

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Phase 2 Completed

Lymphoma, T-Cell, Peripheral

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Peripheral

NCT06702605 2024-11-25

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT04101331 2024-11-05

REDIRECT

Phase 2 Completed

108 enrolled 24 charts

Lymphoma, T-Cell, Peripheral

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase 2 Completed

77 enrolled 20 charts

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

55 enrolled 18 charts

Lymphoma, T-Cell, Peripheral

NCT05140382 2024-08-28

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Phase 2 Completed

52 enrolled 24 charts

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02464228 2024-06-26

PTCL

Phase 2 Completed

65 enrolled 16 charts

Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

LymphoidOther hematologic neoplasm

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01226472 2024-04-25

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Phase 2 Completed

1 enrolled 5 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02653976 2024-01-26

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

67 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT03947255 2023-10-13

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2 Terminated

12 enrolled 17 charts

Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Phase 2 Withdrawn

GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2 Terminated

16 enrolled 16 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05239910 2022-10-17

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Phase 2 Withdrawn

Lymphoma, T-Cell, Peripheral

NCT00865969 2021-10-29

PTCL

Phase 2 Completed

129 enrolled 12 charts

Lymphoma, T-Cell, Peripheral

NCT02676778 2021-07-15

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

Phase 2 Completed

45 enrolled 28 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03502629 2021-03-03

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Phase 2 Unknown

Lymphoma, T-Cell, Peripheral

NCT04457830 2020-10-22

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

Phase 2 Unknown

Lymphoma, T-Cell, Peripheral

NCT00211185 2020-03-18

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase 2 Completed

49 enrolled 11 charts

Lymphoma, T-Cell, Peripheral

NCT00426764 2020-02-11

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Phase 2 Completed

131 enrolled 16 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00364923 2019-12-19

PROPEL

Phase 2 Completed

115 enrolled 11 charts

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02106650 2019-11-20

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Phase 2 Completed

Lymphoma, T-Cell, Peripheral

NCT02495415 2019-07-23

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Phase 2 Unknown

Lymphoma, T-Cell, Peripheral

NCT00421213 2012-07-19

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Phase 2 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Bone Marrow Neoplasms, Hematologic Neoplasms